文献速递免疫规划

RSV-F或hMPV-F糖蛋白与HIV-Gag融合生成的病毒样颗粒在小鼠中显示更好的免疫原性和中和反应

VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
PubMed 文献 · Vaccine · 2024-04-18

研究测试了一种基于病毒样颗粒(VLP)的疫苗平台,该平台将目标免疫原直接融合到HIV结构蛋白Gag上以提高表面密度和免疫原性。在小鼠中比较了以可溶性蛋白或展示于VLP表面的RSV-F或hMPV-F免疫原的免疫原性。VLP相关F蛋白显示出更好的免疫原性并诱导更优的中和反应;在异源方案中联合VLP相关和可溶性免疫原时,VLP相关免疫原作为初免疫苗提供额外益处。

要点

  • VLP相关F蛋白较可溶性蛋白显示更好免疫原性和更优中和反应
  • 异源方案中VLP相关免疫原作为初免提供额外益处
  • 研究为小鼠模型,评估RSV-F和hMPV-F融合HIV-Gag的VLP平台

核心结论

  • VLP相关F蛋白在小鼠中显示更好的免疫原性并诱导更优的中和反应,作为初免时提供额外益处。

研究设计与样本

  • 在小鼠中比较RSV-F或hMPV-F免疫原以可溶性蛋白或展示于VLP表面的免疫原性。

主要发现

  • VLP相关F蛋白较可溶性蛋白显示更好的免疫原性和更优的中和反应。
  • 异源方案中联合VLP相关和可溶性免疫原时,VLP相关免疫原作为初免提供额外益处。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccines have been long overdue. Structure-based vaccine design created a new momentum in the last decade, and the first RSV vaccines have finally been approved in older adults and pregnant individuals. These vaccines are based on recombinant stabilized pre-fusion F glycoproteins administered as soluble proteins. Multimeric antigenic display could markedly improve immunogenicity and should be evaluated in the next generations of vaccines. Here we tested a new virus like particles-based vaccine platform which utilizes the direct fusion of an immunogen of interest to the structural human immunodeficient virus (HIV) protein Gag to increase its surface density and immunogenicity. We compared, in mice, the immunogenicity of RSV-F or hMPV-F based immunogens delivered either as soluble proteins or displayed on the surface of our VLPs. VLP associated F-proteins showed better immunogenicity and induced superior neutralizing responses. Moreover, when combining both VLP associated and soluble immunogens in a heterologous regimen, VLP-associated immunogens provided added benefits when administered as the prime immunization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Trinité B, Durr E, Pons-Grífols A, et al. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice. Vaccine. 2024. PMID: 38641492. doi:10.1016/j.vaccine.2024.04.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。